Dr. Mireille Kamariza is an Assistant Professor in the Department of Bioengineering at UCLA and co-founder and CEO of OliLux Biosciences, a company dedicated to providing low- cost, portable and reliable diagnostic devices in low-resource settings. She is a chemical biologist with expertise building diagnostics tools against infectious organisms. With a background in chemical biology and infectious disease research, she researches new tools to selectively probe molecular activity of live cells, in real-time, with versatile applications in research and medicine.

She was previously a Junior Fellow at the Harvard Society of Fellows working with Prof. Pardis Sabeti at the Broad Institute of Harvard and MIT. There, she worked on developing CRISPR-Cas13 assays to detect bloodborne viruses such as Ebolavirus, Lassa virus, Yellow Fever virus, and many others. 

Prior to her appointment at Harvard, she completed her doctoral studies in Biology at Stanford University where she developed a new diagnostic technology for the rapid and simple detection of tuberculosis at the point-of-care. This project was awarded a Bill & Melinda Gates Foundation grant to test their diagnostic devices in places with high levels of disease. In addition, her work was translated into what is now OliLux Biosciences. 

Dr. Kamariza has received numerous awards, including being named as one of Chemical & Engineering News's Talented 12 in 2020 and Endpt’s 20 under 40 in 2023. In December 2022, Nature Medicine named Dr. Kamariza as one of 11 early-career researchers to watch.